Skip to main content
Erschienen in: Inflammopharmacology 6/2023

16.10.2023 | Original Article

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression

verfasst von: Arto Yuwono Soeroto, Hendarsyah Suryadinata, Theo Audi Yanto, Timotius Ivan Hariyanto

Erschienen in: Inflammopharmacology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Effort to search for the optimal COVID-19 treatment has continuously been attempted. Thymosin alpha-1 have immunomodulatory properties which may be beneficial in case of viral infection. This study’s goal is to determine whether thymosin alpha-1 is effective in treating people with moderate-to-severe COVID-19.

Methods

We searched for literature in 4 database: Scopus, Europe PMC, Medline, ClinicalTrials.gov, and Cochrane Library until March 25th, 2023. If those articles have data on the efficacy of thymosin alpha-1 therapy on COVID-19, they would be included. Risk ratio (RR) and Mean Difference (MD) along with their 95% confidence intervals were used to pool the results of dichotomous and continuous variables, respectively.

Results

Pooled data from 8 studies indicated that moderate to critical Covid-19 patients who were receiving thymosin alpha-1 therapy had significantly lower mortality from COVID-19 (RR 0.59; 95% CI 0.37–0.93, p = 0.02, I2 = 84%), but without any difference in the needs for mechanical ventilation (RR 0.83; 95% CI 0.48–1.44, p = 0.51, I2 = 74%) and hospital length of stay (MD 2.32; 95% CI – 0.93, 5.58, p = 0.16, I2 = 94%) compared to placebo. The benefits of thymosin alpha-1 on the mortality rate were significantly affected only by sample size (p = 0.0000) and sex (p = 0.0117).

Conclusion

Our study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND et al (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clin Epidemiol 10(6):359–368. https://​doi.​org/​10.​2147/​CLEP.​S66677 CrossRef Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND et al (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clin Epidemiol 10(6):359–368. https://​doi.​org/​10.​2147/​CLEP.​S66677 CrossRef
Zurück zum Zitat Mustafa H, Hamza A, Shah NN, Samreen S, Din W (2022) Evaluation of role of thymosin alpha 1 in moderate to severe COVID-19 patients: a retrospective study. Eur J Mol Clin Med 9(3):11870–11876 Mustafa H, Hamza A, Shah NN, Samreen S, Din W (2022) Evaluation of role of thymosin alpha 1 in moderate to severe COVID-19 patients: a retrospective study. Eur J Mol Clin Med 9(3):11870–11876
Metadaten
Titel
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
verfasst von
Arto Yuwono Soeroto
Hendarsyah Suryadinata
Theo Audi Yanto
Timotius Ivan Hariyanto
Publikationsdatum
16.10.2023
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 6/2023
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01354-2

Weitere Artikel der Ausgabe 6/2023

Inflammopharmacology 6/2023 Zur Ausgabe